摘要
目的探讨血浆平足蛋白(sPDPN)作为新型生物标志物在胃肠道肿瘤相关静脉血栓栓塞(VTE)风险评估、早期诊断和治疗监控中的应用价值。方法纳入2020年11月—2021年12月于徐州医科大学第二附属医院初诊胃肠道肿瘤患者102例,另选同期我院100例体检健康志愿者作为对照,应用小鼠抗人PDPN单克隆抗体SZ163和SZ168建立的酶联免疫吸附试验(ELISA)检测患者手术前后sPDPN含量,并联合Caprini量表评估术后VTE风险。结果术前胃肠道肿瘤患者sPDPN水平高于对照组(P<0.01),术后第7天该指标降低,与对照组相比差异无统计学意义(P>0.05)。sPDPN联合Caprini量表评估VTE风险诊断价值高(AUC为0.929,敏感度为85.90%,特异度为94.61%),优于单一指标评估。结论sPDPN有望成为胃肠道肿瘤相关VTE的新型血浆标志物,在肿瘤相关VTE风险评估、早期诊断和治疗监控中具有一定的临床应用价值。
Objective To investigate the clinical value of plasma soluble podoplanin(sPDPN)as a novel biomarker for assessing the risk,early diagnosis,and therapeutic monitoring of venous thromboembolism(VTE)associated with gastrointestinal tumors.Methods A total of 102 patients who were initially diagnosed with gastrointestinal tumors at the Second Affiliated Hospital of Xuzhou Medical University from November 2020 to December 2021 were enrolled.Meanwhile,100 healthy volunteers undergoing routine physical examinations were included as controls.The levels of plasma sPDPN before and after surgery were measured by enzyme-linked immunosorbent assay(ELISA)using mouse anti-human PDPN monoclonal antibodies SZ163 and SZ168.Postoperative VTE risk was evaluated using the Caprini risk assessment model.Results Preoperative sPDPN levels in patients with gastrointestinal tumors were significantly higher than those in the control group(P<0.01).On postoperative day 7,sPDPN levels decreased and showed no significant difference compared with those in the control group(P>0.05).The combination of sPDPN and the Caprini score demonstrated a higher diagnostic value for VTE risk(AUC=0.929,sensitivity=85.90%,specificity=94.61%)than either indicator alone.Conclusions sPDPN may serve as a novel plasma biomarker for tumor-associated VTE and holds potential clinical value in VTE risk assessment,early diagnosis,and therapeutic monitoring among patients with gastrointestinal tumors.
作者
赵塞
董圆
石林
张晨
邵子琪
李曹毅
李真
赵益明
王建
ZHAO Sai;DONG Yuan;SHI Lin;ZHANG Chen;SHAO Ziqi;LI Caoyi;LI Zhen;ZHAO Yiming;WANG Jian(Department of General Surgery,the Second Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu 221006,China;Central Laboratory,the Second Affiliated Hospital of Xuzhou Medical University;Department of Oncology,the Second Affiliated Hospital of Xuzhou Medical University;The First Affiliated Hospital of Soochow University,Jiangsu Blood Institute,Suzhou,Jiangsu 215000)
出处
《徐州医科大学学报》
2025年第10期730-734,共5页
Journal of Xuzhou Medical University
基金
国家自然科学基金(81873431)
江苏省卫生健康委科研项目(ZDB2020030)。
